Standard

Plasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy. / Illarionov, Roman A.; Pachuliia, Olga V.; Vashukova, Elena S.; Tkachenko, Alexander A.; Maltseva, Anastasia R.; Postnikova, Tatyana B.; Nasykhova, Yulia A.; Bespalova, Olesya N.; Glotov, Andrey S.

In: Genes, Vol. 13, No. 11, 2018, 03.11.2022.

Research output: Contribution to journalArticlepeer-review

Harvard

Illarionov, RA, Pachuliia, OV, Vashukova, ES, Tkachenko, AA, Maltseva, AR, Postnikova, TB, Nasykhova, YA, Bespalova, ON & Glotov, AS 2022, 'Plasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy', Genes, vol. 13, no. 11, 2018. https://doi.org/10.3390/genes13112018

APA

Illarionov, R. A., Pachuliia, O. V., Vashukova, E. S., Tkachenko, A. A., Maltseva, A. R., Postnikova, T. B., Nasykhova, Y. A., Bespalova, O. N., & Glotov, A. S. (2022). Plasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy. Genes, 13(11), [2018]. https://doi.org/10.3390/genes13112018

Vancouver

Illarionov RA, Pachuliia OV, Vashukova ES, Tkachenko AA, Maltseva AR, Postnikova TB et al. Plasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy. Genes. 2022 Nov 3;13(11). 2018. https://doi.org/10.3390/genes13112018

Author

Illarionov, Roman A. ; Pachuliia, Olga V. ; Vashukova, Elena S. ; Tkachenko, Alexander A. ; Maltseva, Anastasia R. ; Postnikova, Tatyana B. ; Nasykhova, Yulia A. ; Bespalova, Olesya N. ; Glotov, Andrey S. / Plasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy. In: Genes. 2022 ; Vol. 13, No. 11.

BibTeX

@article{01b5f3353a3b4ac7bb552160116617e2,
title = "Plasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy",
abstract = "In recent years evidence has been accumulated showing that miRNAs can act as potential biomarkers or targets for therapy of preterm birth, one of the most important problems in modern obstetrics. We have performed a prospective study of the miRNA profile in the plasma during the first and second trimesters in pregnant women with high risk of preterm birth (n = 13 cases and n = 11 controls). For the study group plasma blood samples at 9–13 weeks before diagnosis and at 22–24 weeks after start of therapy were selected. Using high-throughput sequencing technology we detected differences in the levels of 15 miRNAs (3 upregulated—hsa-miR-122-5p, hsa-miR-34a-5p, hsa-miR-34c-5p; 12 downregulated—hsa-miR-487b-3p, hsa-miR-493-3p, hsa-miR-432-5p, hsa-miR-323b-3p, hsa-miR-369-3p, hsa-miR-134-5p, hsa-miR-431-5p, hsa-miR-485-5p, hsa-miR-382-5p, hsa-miR-369-5p, hsa-miR-485-3p, hsa-miR-127-3p) (log2(FC) ≥ 1.5; FDR ≤ 0.05) during the first trimester compared with the control (non-high-risk of preterm birth pregnant women). All downregulated miRNAs in the first trimester from the placenta-specific C14MC cluster. During the second trimester no differentially expressed miRNAs were found. Our results suggest that the miRNA profile in plasma during early pregnancy may predict a high risk of preterm birth, which is important in preventing gestational problems as early as possible.",
keywords = "blood plasma, high risk of preterm birth, high-throughput sequencing, miRNA, pregnancy, Premature Birth/genetics, MicroRNAs/genetics, Prospective Studies, Humans, Pregnancy, Biomarkers, Female, High-Throughput Nucleotide Sequencing, Infant, Newborn",
author = "Illarionov, {Roman A.} and Pachuliia, {Olga V.} and Vashukova, {Elena S.} and Tkachenko, {Alexander A.} and Maltseva, {Anastasia R.} and Postnikova, {Tatyana B.} and Nasykhova, {Yulia A.} and Bespalova, {Olesya N.} and Glotov, {Andrey S.}",
note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",
year = "2022",
month = nov,
day = "3",
doi = "10.3390/genes13112018",
language = "English",
volume = "13",
journal = "Genes",
issn = "2073-4425",
publisher = "MDPI AG",
number = "11",

}

RIS

TY - JOUR

T1 - Plasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy

AU - Illarionov, Roman A.

AU - Pachuliia, Olga V.

AU - Vashukova, Elena S.

AU - Tkachenko, Alexander A.

AU - Maltseva, Anastasia R.

AU - Postnikova, Tatyana B.

AU - Nasykhova, Yulia A.

AU - Bespalova, Olesya N.

AU - Glotov, Andrey S.

N1 - Publisher Copyright: © 2022 by the authors.

PY - 2022/11/3

Y1 - 2022/11/3

N2 - In recent years evidence has been accumulated showing that miRNAs can act as potential biomarkers or targets for therapy of preterm birth, one of the most important problems in modern obstetrics. We have performed a prospective study of the miRNA profile in the plasma during the first and second trimesters in pregnant women with high risk of preterm birth (n = 13 cases and n = 11 controls). For the study group plasma blood samples at 9–13 weeks before diagnosis and at 22–24 weeks after start of therapy were selected. Using high-throughput sequencing technology we detected differences in the levels of 15 miRNAs (3 upregulated—hsa-miR-122-5p, hsa-miR-34a-5p, hsa-miR-34c-5p; 12 downregulated—hsa-miR-487b-3p, hsa-miR-493-3p, hsa-miR-432-5p, hsa-miR-323b-3p, hsa-miR-369-3p, hsa-miR-134-5p, hsa-miR-431-5p, hsa-miR-485-5p, hsa-miR-382-5p, hsa-miR-369-5p, hsa-miR-485-3p, hsa-miR-127-3p) (log2(FC) ≥ 1.5; FDR ≤ 0.05) during the first trimester compared with the control (non-high-risk of preterm birth pregnant women). All downregulated miRNAs in the first trimester from the placenta-specific C14MC cluster. During the second trimester no differentially expressed miRNAs were found. Our results suggest that the miRNA profile in plasma during early pregnancy may predict a high risk of preterm birth, which is important in preventing gestational problems as early as possible.

AB - In recent years evidence has been accumulated showing that miRNAs can act as potential biomarkers or targets for therapy of preterm birth, one of the most important problems in modern obstetrics. We have performed a prospective study of the miRNA profile in the plasma during the first and second trimesters in pregnant women with high risk of preterm birth (n = 13 cases and n = 11 controls). For the study group plasma blood samples at 9–13 weeks before diagnosis and at 22–24 weeks after start of therapy were selected. Using high-throughput sequencing technology we detected differences in the levels of 15 miRNAs (3 upregulated—hsa-miR-122-5p, hsa-miR-34a-5p, hsa-miR-34c-5p; 12 downregulated—hsa-miR-487b-3p, hsa-miR-493-3p, hsa-miR-432-5p, hsa-miR-323b-3p, hsa-miR-369-3p, hsa-miR-134-5p, hsa-miR-431-5p, hsa-miR-485-5p, hsa-miR-382-5p, hsa-miR-369-5p, hsa-miR-485-3p, hsa-miR-127-3p) (log2(FC) ≥ 1.5; FDR ≤ 0.05) during the first trimester compared with the control (non-high-risk of preterm birth pregnant women). All downregulated miRNAs in the first trimester from the placenta-specific C14MC cluster. During the second trimester no differentially expressed miRNAs were found. Our results suggest that the miRNA profile in plasma during early pregnancy may predict a high risk of preterm birth, which is important in preventing gestational problems as early as possible.

KW - blood plasma

KW - high risk of preterm birth

KW - high-throughput sequencing

KW - miRNA

KW - pregnancy

KW - Premature Birth/genetics

KW - MicroRNAs/genetics

KW - Prospective Studies

KW - Humans

KW - Pregnancy

KW - Biomarkers

KW - Female

KW - High-Throughput Nucleotide Sequencing

KW - Infant, Newborn

UR - http://www.scopus.com/inward/record.url?scp=85141554913&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/56333ef5-767b-3231-8f6e-d9dc70115f26/

U2 - 10.3390/genes13112018

DO - 10.3390/genes13112018

M3 - Article

C2 - 36360255

AN - SCOPUS:85141554913

VL - 13

JO - Genes

JF - Genes

SN - 2073-4425

IS - 11

M1 - 2018

ER -

ID: 100508627